For media inquiries, please contact Matt Middleman at:



Date Title
Nov 27 Healio Rheumatology: Lorecivivint yields improved patient-reported outcome scores in knee OA
Nov 14 HCPLive: Lorecivivint a Potential Novel Treatment for Knee Osteoarthritis
Nov 13 Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
Oct 02 Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors
Sep 12 DDNews: A strong showing for SM07883
Aug 15 FierceBiotech: In Conversation with Samumed CEO Osman Kibar: Drugging Wnt, Restoring Youth and Unconventional Capital
Aug 14 Xtalks: Tackling Multiple Pathways with One Alzheimer’s Drug
Aug 05 Technology Networks: Therapeutically Targeting DYRK1A in Alzheimer’s Disease
Jul 24 Alzheimer's News Today: Samumed’s SM07883 Can Prevent Tau-Mediated Neuroinflammation, Neurodegeneration in Mice, Study Shows
Jul 18 Samumed Announces Publication of Preclinical Data Demonstrating That SM07883 is a Potential Treatment for Alzheimer’s Disease
Jun 19 Samumed Doses First Subject in Phase 3 STRIDES-X-ray Trial of Lorecivivint for the Treatment of Knee Osteoarthritis
May 02 Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
Apr 10 Samumed Announces Multiple Presentations at the 19th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Apr 10 Alzheimer's News Today: Phase 1 Trial of Alzheimer’s Candidate SM07883 Doses First Participant
Apr 04 Samumed Doses First Subject in Phase 1 Trial of SM07883, a Potential Treatment for Alzheimer’s Disease
Mar 27 The Rheumatologist: SM04690 Promising for Knee OA
Mar 07 Samumed to Present Clinical Data on SM04690 at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Feb 28 Samumed Announces Positive End-of-Phase 2 Meeting with FDA for SM04690 in Knee Osteoarthritis
Jan 29 Samumed to Present Novel Biological Targets of SM04690 for Treatment of Knee Osteoarthritis
Jan 03 Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer


Date Title
Nov 19 Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia
Nov 05 Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)
Oct 24 Samumed Phase 2b Trial in Knee Osteoarthritis Meets Primary Endpoints
Oct 18 Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Congress
Oct 16 Samumed to Present Data from Phase 2b Trial of SM04690 for Treatment of Knee Osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting
Oct 15 Samumed Announces Sponsorship of Knee Osteoarthritis Registry Study
Sep 17 Samumed and United Therapeutics Announce North American License Agreement for Samumed’s IPF Drug Candidate
Aug 06 Samumed Closes on $438 Million in Equity Financing
Jul 27 Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)
Jul 17 Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer’s Disease Candidate, at the Alzheimer’s Association International Conference® (AAIC®) 2018
Jun 29 Samumed Announces Presentation of Clinical Data Analysis on SM04690 for Treatment of Knee Osteoarthritis at International Workshop on Osteoarthritis Imaging (IWOAI) 2018 Conference
Jun 20 Samumed Presents Clinical and Preclinical Data at European League Against Rheumatism (EULAR) 2018 Annual Congress
Jun 08 Samumed Announces Multiple Presentations at the European League Against Rheumatism (EULAR) 2018 Annual Congress
May 31 Samumed to Present Data on Multiple Product Candidates in Five Presentations at The Orthobiologic Institute (TOBI) 2018 Annual Symposium
May 11 Samumed Announces Presentation at the 2018 American Thoracic Society (ATS) International Conference
May 07 Samumed Presented Multiple Abstracts Supporting Potential Disease Modification at the Osteoarthritis Research Society International (OARSI) 2018 World Congress
May 03 Scrip Pharma Intelligence: Samumed CMO Hopes to Reach Drug Approvals via the Wnt Pathway
Apr 27 Samumed's CEO Presents at Unite to Cure: Fourth International Vatican Conference
Apr 23 Samumed’s Osteoarthritis and Tendinopathy Research Selected for Multiple Presentations at the 2018 Osteoarthritis Research Society International (OARSI) World Congress


Date Title
Dec 18 Samumed Doses First Patient in Phase 1 Trial of SM04690 for Treatment of Degenerative Disc Disease
Dec 11 Samumed Doses First Patient in Phase 1 Trial of SM08502 for Treatment of Advanced Solid Tumors
Nov 17 Samumed Announces Collaboration with L'Oréal for Development of SM05253 for Anti-Wrinkle Skin Care Applications
Oct 31 Samumed Initiates Phase 1b Trial of SM04755 for Treatment of Psoriasis
Oct 24 Samumed Announces 52-week Phase 2 Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug
Oct 05 Nature Reviews Rheumatology: Wnt Inhibitor Shows Potential as a DMOAD
Jul 27 Samumed Successfully Completed 52-week Phase 2 Study for Treatment of Osteoarthritis of the Knee
Jul 25 FDA Grants Orphan Drug Designation to Samumed’s Investigational SM04646 for IPF Treatment
Jul 24 Samumed Receives Orphan Drug Designation from FDA for SM04646 as a Treatment for Idiopathic Pulmonary Fibrosis (IPF)
Jul 21 Samumed Successfully Completes Phase 1 Study for Potential Topical Treatment for Chronic Tendinopathy
Jul 20 Samumed and IHS Markit Present Analysis of Medicare Claims Data for Knee OA
Jul 17 Samumed Successfully Completed Phase 1 Study for the Potential Treatment of Idiopathic Pulmonary Fibrosis
Jun 20 Samumed Selected for Four Presentations at European League Against Rheumatism (EULAR) 2017 Annual Meeting
Jun 20 EULAR 2017: Osteoarthritis Pipeline Product Shows Promise
Apr 02 A $12 Billion Startup You've Probably Never Heard Wants to Cure Baldness and Smooth Out Your Wrinkles
Mar 15 Samumed’s CEO Presents at Near Future Summit 2017
Mar 06 Samumed Presented Data on Increases in Hair Follicles Observed in Its Phase 2 Biopsy Study for a Potential Treatment of Androgenetic Alopecia (AGA) at Annual Meeting of the American Academy of Dermatology (AAD)